Distinguished in Myeloproliferative Neoplasms (MPN)

David M. Ross

D Bedford Park, 
Adelaide, SA, AU 
Distinguished in Myeloproliferative Neoplasms (MPN)
D Bedford Park, 
Adelaide, SA, AU 
OverviewLocationsClinical Research

Overview

David Ross practices in Adelaide, Australia. Mr. Ross is rated as a Distinguished expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Myelofibrosis, Leukemia, Bone Marrow Transplant, and Cardiac Ablation.

His clinical research consists of co-authoring 140 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Myeloproliferative Neoplasms (MPN).

Gender
Male

Locations

D Bedford Park, Adelaide, SA, Australia
Other Locations
SA Pathology, PO Box 14, Rundle Mall, Adelaide, SA 5000, Australia
Bedford Park, Adelaide, SA, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: IMG-7289 LSD1 Inhibitor
Study Phase: Phase 1/Phase 2
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies
Enrollment Status: Completed
Publish Date: July 11, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

140 Total Publications

Clinical and biological predictors of treatment-free remission in CML.
Clinical and biological predictors of treatment-free remission in CML.
Journal: Leukemia & lymphoma
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ross's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile